Citadel Advisors’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q3 | – | Sell |
-321,200
| Closed | -$12.6M | – | 15615 |
|
|
2023
Q2 | $12.6M | Buy |
321,200
+89,000
| +38% | +$3.14M | ﹤0.01% | 2378 |
|
|
2023
Q1 | $5.65M | Sell |
232,200
-113,900
| -33% | -$2.49M | ﹤0.01% | 3600 |
|
|
2022
Q4 | $7.41M | Sell |
346,100
-140,400
| -29% | -$3M | ﹤0.01% | 3239 |
|
|
2022
Q3 | $8.73M | Buy |
486,500
+221,900
| +84% | +$2.91M | ﹤0.01% | 2966 |
|
|
2022
Q2 | $2.54M | Buy |
264,600
+158,200
| +149% | +$1.99M | ﹤0.01% | 5060 |
|
|
2022
Q1 | $1.79M | Buy |
106,400
+69,700
| +190% | +$1.03M | ﹤0.01% | 6324 |
|
|
2021
Q4 | $614K | Sell |
36,700
-57,700
| -61% | -$946K | ﹤0.01% | 9171 |
|
|
2021
Q3 | $1.53M | Buy |
94,400
+71,100
| +305% | +$774K | ﹤0.01% | 7033 |
|
|
2021
Q2 | $147K | Sell |
23,300
-26,000
| -53% | -$168K | ﹤0.01% | 12529 |
|
|
2021
Q1 | $305K | Sell |
49,300
-132,000
| -73% | -$801K | ﹤0.01% | 10822 |
|
|
2020
Q4 | $1.25M | Buy |
181,300
+39,800
| +28% | +$255K | ﹤0.01% | 6316 |
|
|
2020
Q3 | $798K | Buy |
141,500
+93,200
| +193% | +$444K | ﹤0.01% | 6427 |
|
|
2020
Q2 | $246K | Buy |
48,300
+29,900
| +163% | +$125K | ﹤0.01% | 8238 |
|
|
2020
Q1 | $63K | Sell |
18,400
-34,800
| -65% | -$203K | ﹤0.01% | 8920 |
|
|
2019
Q4 | $456K | Buy |
+53,200
| New | +$190K | ﹤0.01% | 6965 |
|
|
2019
Q1 | – | Sell |
-13,900
| Closed | -$17K | – | 10068 |
|
|
2018
Q4 | $17K | Buy |
13,900
+1,900
| +16% | +$3.68K | ﹤0.01% | 8809 |
|
|
2018
Q3 | $28K | Sell |
12,000
-3,900
| -25% | -$9.72K | ﹤0.01% | 8951 |
|
|
2018
Q2 | $43K | Buy |
+15,900
| New | +$43.9K | ﹤0.01% | 8470 |
|
|
2018
Q1 | – | Sell |
-22,700
| Closed | -$71K | – | 8951 |
|
|
2017
Q4 | $71K | Sell |
22,700
-800
| -3% | -$2.25K | ﹤0.01% | 7534 |
|
|
2017
Q3 | $66K | Sell |
23,500
-1,900
| -7% | -$5.13K | ﹤0.01% | 7130 |
|
|
2017
Q2 | $65K | Buy |
25,400
+900
| +4% | +$2.45K | ﹤0.01% | 7028 |
|
|
2017
Q1 | $90K | Sell |
24,500
-95,000
| -79% | -$401K | ﹤0.01% | 6903 |
|
|
2016
Q4 | $577K | Buy |
119,500
+87,600
| +275% | +$2.6M | ﹤0.01% | 4686 |
|
|
2016
Q3 | $1.47M | Buy |
31,900
+3,400
| +12% | +$192K | ﹤0.01% | 3336 |
|
|
2016
Q2 | $1.45M | Sell |
28,500
-1,800
| -6% | -$89.4K | ﹤0.01% | 3098 |
|
|
2016
Q1 | $1.28M | Buy |
30,300
+12,700
| +72% | +$647K | ﹤0.01% | 3172 |
|
|
2015
Q4 | $1.38M | Sell |
17,600
-5,500
| -24% | -$318K | ﹤0.01% | 3186 |
|
|
2015
Q3 | $936K | Buy |
23,100
+5,100
| +28% | +$270K | ﹤0.01% | 3904 |
|
|
2015
Q2 | $937K | Buy |
18,000
+7,300
| +68% | +$363K | ﹤0.01% | 4042 |
|
|
2015
Q1 | $498K | Buy |
10,700
+4,900
| +84% | +$254K | ﹤0.01% | 4917 |
|
|
2014
Q4 | $260K | Sell |
5,800
-15,500
| -73% | -$651K | ﹤0.01% | 5639 |
|
|
2014
Q3 | $829K | Buy |
21,300
+13,700
| +180% | +$538K | ﹤0.01% | 3951 |
|
|
2014
Q2 | $322K | Buy |
+7,600
| New | +$279K | ﹤0.01% | 4981 |
|
Citadel Advisors's ISEE Position: Q3 2023 in Review
Citadel Advisors sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2023, closing a stake of 299,796 shares — an estimated $11.8M sold.
Citadel Advisors first reported a position in ISEE in Q3 2013 and held it in 30 quarters. The position peaked at $45.9M in Q3 2022. 0 funds tracked by Wall St. Rank hold ISEE as of Q3 2023.
- Citadel Advisors reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
- Citadel Advisors sold 299,796 IVERIC bio, Inc. Common Stock shares in Q3 2023, an estimated $11.8M.
- Citadel Advisors first reported a position in IVERIC bio, Inc. Common Stock in Q3 2013 and held it in 30 quarters.
- Citadel Advisors's IVERIC bio, Inc. Common Stock position peaked at $45.9M in Q3 2022.
- 0 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2023.
Based on Citadel Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.